Compare · BNTX vs KYMR
BNTX vs KYMR
Side-by-side comparison of BioNTech SE (BNTX) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.66B, about 2.5x KYMR ($8.99B).
- BNTX has been more active in the news (11 items in the past 4 weeks vs 2 for KYMR).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Kymera Therapeutics Inc.
- Price
- $87.69-2.80%
- $104.71-3.10%
- Market cap
- $22.66B
- $8.99B
- 1M return
- -11.18%
- -
- 1Y return
- -16.64%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
Latest KYMR
- Raymond James initiated coverage on Kymera Therapeutics with a new price target
- Chief Executive Officer Mainolfi Nello exercised 30,000 shares at a strike of $2.08 and sold $3,413,917 worth of shares (30,000 units at $113.80) as part of a pre-agreed trading plan (SEC Form 4)
- Kymera Therapeutics upgraded by Wolfe Research with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.
- Chief Legal Officer Adams Brian sold $744,297 worth of shares (6,371 units at $116.83), decreasing direct ownership by 11% to 50,254 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Kymera Therapeutics Inc.
- SEC Form 144 filed by Kymera Therapeutics Inc.
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences
- Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
- Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.